U.S. President Donald Trump speaks about the U.S. government shutdown, during the swearing-in ceremony for Sergio Gor as U.S. Ambassador to India, at the White House in Washington, D.C., U.S., Nov. 10, 2025.
Kevin Lamarque | Reuters
U.S. President Donald Trump bought at least $82 million in corporate and municipal bonds from late August to early October including new investments in sectors benefiting from his policies, financial disclosures made public on Saturday showed.
According to the forms released by the U.S. Office of Government Ethics, Trump carried out more than 175 financial purchases from Aug. 28 through Oct. 2. The disclosures, made under a 1978 transparency law called the Ethics in Government Act, do not list exact amounts for each purchase, only providing a broad range.
The maximum total value of the bond purchases exceeded $337 million, according to the filings.
Most of the assets listed in Saturday’s disclosures consist of bonds issued by municipalities, states, counties, school districts and other entities with ties to public agencies.
Trump’s new bond investments span several industries, including sectors that have already benefited, or are benefiting, from his administration’s policy changes such as financial deregulation.
Corporate bonds acquired by Trump include offerings from chipmakers such as Broadcom and Qualcomm; tech companies such as Meta Platforms; retailers such as Home Depot and CVS Health; and Wall Street banks such as Goldman Sachs and Morgan Stanley. Purchases of the debt of investment banks in late August included bonds of JPMorgan.
On Friday, Trump asked the U.S. Justice Department to investigate JP Morgan over its ties to the late financier and convicted sex offender Jeffrey Epstein. The bank has said it regrets its past ties with Epstein and did not help him commit “heinous acts.”
Trump also acquired Intel bonds after the U.S. government, under Trump’s direction, acquired a stake in the company.
The White House did not immediately respond to a request for comment on Saturday. The administration has said before that Trump has continued to file mandatory disclosures about his investments but that neither he nor his family has a role in running the portfolio, which is managed by a third-party financial institution.
Trump, who became wealthy in the real estate sector before entering politics, has previously said that he placed his companies into a trust overseen by his children.
A disclosure filed in August indicated that Trump had purchased more than $100 million in bonds since returning to the presidency on Jan. 20. Trump also submitted his annual disclosure form in June, which indicated that income from his various ventures still ultimately goes to him, raising concerns of potential conflicts of interest.
In that annual disclosure, which appeared to cover the 2024 calendar year, Trump reported more than $600 million in income from cryptocurrencies, golf properties, licensing and other ventures. It also showed Trump’s push into crypto had added substantially to his wealth.
Overall, the president’s June disclosure reported assets worth at least $1.6 billion, according to a Reuters calculation at the time.
Prada (SEHK:1913) shares have seen some movement lately. This has caught the attention of investors interested in how the luxury retailer’s performance stacks up over the past month. Recent price changes raise questions about current valuation.
See our latest analysis for Prada.
Zooming out, Prada’s 1-day share price drop of 2.57% comes after some bumpy trading. The bigger story is the year-to-date slump of over 25%. Despite this rough patch, the three- and five-year total shareholder returns of 24% and 43% still show the brand’s longer-term growth story. Momentum has cooled lately as investors reassess both risk and value.
If Prada’s swings have you curious, this could be the perfect moment to broaden your search and discover fast growing stocks with high insider ownership
With shares trading at a notable discount to analyst price targets, but recent growth trending down, investors might wonder if Prada is currently undervalued or if the market has already priced in all its future potential.
Compared to Prada’s recent closing price, the most widely followed narrative suggests significant upside potential if key drivers play out as expected. Market participants are watching to see if the brand can leverage growth catalysts to justify this gap.
Prada’s ongoing investment in new product collections, broadening price points and enhancing personalization (for example, make-to-measure and bespoke in flagship stores), positions the group to capture growth from both affluent core clients and younger, aspirational demographics globally, supporting long-term revenue and gross margin expansion.
Read the complete narrative.
Want to know the forces shaping this bullish outlook? Dynamic expansion plans and bold profitability bets fuel the case for a higher valuation. Scratch beneath the surface and you’ll discover key financial assumptions powering that fair value. Ready to see what sets this narrative apart?
Result: Fair Value of $63.22 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, lingering risks such as volatile tourism patterns and rising costs could quickly disrupt growth assumptions and challenge the bullish narrative around Prada.
Find out about the key risks to this Prada narrative.
While fair value estimates suggest Prada is undervalued, the lens changes when looking at the price-to-earnings ratio. Prada trades at 15.8 times earnings, more expensive than both the Hong Kong Luxury industry average of 10.1 and the suggested fair ratio of 11.9. This premium points to higher valuation risk. Does the market expect more than fundamentals can deliver?
See what the numbers say about this price — find out in our valuation breakdown.
SEHK:1913 PE Ratio as at Nov 2025
If you think your perspective differs or enjoy digging into the numbers yourself, you can craft your own take in just a few minutes, and Do it your way
A great starting point for your Prada research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
When you’re ready to boost your portfolio, don’t settle for the usual picks. There are unique stocks waiting to be found with the Simply Wall Street Screener. You could be missing out on the next breakout winner if you only stick with the obvious choices.
Tap into companies reshaping healthcare by checking out these 31 healthcare AI stocks and see how artificial intelligence is transforming patient outcomes and the business of medicine.
Unlock fresh opportunities in the digital asset world by exploring these 82 cryptocurrency and blockchain stocks, where innovators are building secure payment networks and powering the future of finance.
Maximize your portfolio’s potential for steady income. See which firms are offering strong yields with these 16 dividend stocks with yields > 3% to strengthen your investment approach.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 1913.HK.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
“Rich Dad Poor Dad,” author Robert Kiyosaki has once again sparked conversation online with unrestrained financial advice aimed at those struggling with poverty. In a recent post on X, he said, “While I feel for poor people … I do not believe in giving poor people money.”
Kiyosaki used the post to promote silver as an affordable investment, especially compared to assets like Bitcoin. “Most people in the world … even poor people can afford $50 in silver,” he wrote. He predicted silver could climb from $50 to $70, and possibly even $200 an ounce, within a year.
Don’t Miss:
“When silver is $200 an ounce … losers will begin buying,” he warned. “Please do not be [a] loser. Buy when prices are low… Sell when losers are buying.”
The personal finance author said his approach follows his “rich dad’s” investment philosophy: “Your profit is made when you buy … not when you sell.”
He contrasted silver with Bitcoin, which he said is now too expensive for most. According to Kiyosaki, he bought his first Bitcoin at $6,000 and now holds at least 100 of them, which he says are worth millions. “If I could not afford a $100k Bitcoin, I would be excited about my precious X prediction of silver going from $50 to $70,” he added.
Kiyosaki backed up his stance with the old saying: “Give a person a fish… you feed them for a day. Teach a person to fish… you feed them for life.”
Trending: Bill Gates Invests Billions in Green Tech — This Tree-Free Material Could Be the Next Big Breakthrough
The author shared his philosophy in other posts from earlier this year, warning that poor people often break what he calls the “two most important laws of money.”
He cited Gresham’s Law: “When bad money enters a system … good money goes into hiding,” using this to justify why he doesn’t save U.S. dollars. Instead, he saves “real money” like gold, silver, and Bitcoin.
He also pointed to Metcalfe’s Law, which values the power of networks. According to Kiyosaki, rich people invest in strong networks like Bitcoin or McDonald’s (NYSE:MCD), while poor people often operate alone, like a single-truck delivery service.
See Also: Wall Street’s $12B Real Estate Manager Is Opening Its Doors to Individual Investors — Without the Crowdfunding Middlemen
Even while delivering hard truths, Kiyosaki has shown sympathy in other posts. After Challenger, Gray & Christmas recently reported that 153,000 Americans are set to be laid off, he urged compassion. “If you know someone who is fired, especially over this holiday season, please be extra kind and generous,” he wrote.
(Bloomberg) — European Union officials may cut growth forecasts for 2026 in the coming week in an assessment of damage to the region’s economy, a year after Donald Trump won back the White House.
The outlook to be released in Brussels on Monday will point to the cumulative impact of trade threats and higher tariffs imposed by the US, along with the challenges of persistent weakness in Germany and political turmoil in France.
Forecasts released in May were already downbeat in the wake of President Trump’s market-jolting “Liberation Day” announcement of levies the previous month, followed by a climbdown as he suspended action to pursue deals. In their own accord with the US clinched in July, Brussels officials ended up swallowing 15% tariffs on most EU goods.
The fallout for 2025 has ended up being less severe than feared. The European Commission earlier predicted a 0.9% increase for gross domestic product in the euro area, and it’s likely to raise that estimate this time around.
For 2026, though, hopes of a mild pickup to the 1.4% predicted in May are now looking unlikely, with the European Central Bank having anticipated 1% growth in its last forecasting round in September.
Describing the challenges for the current quarter, Frankfurt officials said at their last meeting that “still-elevated uncertainty, higher effective tariffs, a stronger euro and increased global competition are expected to hold back growth.”
Trade uncertainty is just one part of the story. Despite a spending binge on defense and infrastructure in Europe’s biggest economy, what could have been Germany’s first meaningful year of growth since the aftermath of the pandemic is now looking less impressive. The government’s Council of Economic Experts has lowered its outlook for expansion in 2026 to below 1%.
In France, Europe’s No. 2 economy, political instability is an ongoing challenge. While growth there is proving resilient, uncertainty is shaving about 0.5 percentage point off expansion, with domestic political and budget turbulence accounting for at least 0.2 point of that, according to the Bank of France.
France is likely to own the region’s worst deficit in the EU’s outlook for public finances. One bright spot is Italy, which has brought its own shortfall down to the bloc’s 3% ceiling faster than anticipated, and may even get an upgrade from Moody’s Ratings on Friday.
What Bloomberg Economics Says:
“We forecast euro-area GDP growth to remain below trend in the final quarter of 2025 at 0.1%. The economy may experience another period of soft business investment and weak external demand as a result of elevated uncertainty and fewer purchases from the other side of the Atlantic.”
—For full preview, click here
Elsewhere, a possible contraction in Japanese GDP, slowing UK inflation, long-delayed US jobs numbers and possible interest rate cuts from Egypt to South Africa may be among the highlights.
Click here for what happened in the past week, and below is our wrap of what’s coming up in the global economy.
US and Canada
Investors and policymakers continue to wait on further updates to economic data calendars by official statistics agencies. The Bureau of Labor Statistics said it will release the September jobs report on Thursday; the Census Bureau announced it will move forward with reports on August construction spending, factory orders and the trade balance.
Government funding resumed days ago following the longest shutdown in US history, but agencies are running behind on most data collection for key October reports on employment and inflation. The process of catching up will likely stretch well into November on economic information that in any event is growing increasingly stale.
The dearth of official data helps explain recent comments by a number of Federal Reserve policymakers that they should hold the line on interest rates when the meet next month. The Fed on Wednesday will issue minutes of its October meeting.
Among upcoming private-sector data, figures from the National Association of Realtors on Thursday are projected to show little change in October sales of previously-owned homes. The report is expected to illustrate a housing market still challenged by limited affordability.
In Canada, data may show inflation above the central bank’s 2% target for October, even as officials expect the headline rate to average 2% in the fourth quarter. Policymakers have said rates are at “about the right level” as long as their economic and inflation forecasts play out, so there would need to be a significant downside surprise to move them off the sidelines at their Dec. 10 meeting.
Existing home sales and housing starts data will offer a look at Canada’s tepid real estate market, while retail data will shed light on how consumption is holding up amid the trade war with the US.
Prime Minister Mark Carney’s big-spending budget is expected to narrowly pass the House of Commons.
For more, read Bloomberg Economics’ full Week Ahead for the US Asia
The week begins with data that’s likely to show Japan’s economy shrank at an annualized pace of 2.4% in the three months through September, the first contraction since early 2024.
The figures will give Prime Minister Sanae Takaichi the impetus she needs to compile an outsized stimulus package, to be unveiled later this month.
On the same day, data from Bangkok are expected to show that Thailand’s economic growth slowed to 1.7% year on year in the third quarter, weighed down by sagging tourism numbers and US tariffs.
Among key inflation gauges, Japan releases consumer price figures forecast to show gains stayed at or above the central bank’s 2% target for a 43rd straight month in October, keeping authorities on the path toward rate hikes.
November purchasing managers index figures will likely show India’s manufacturing activity staying expansionary, while Japan’s may remain just below the boom-or-bust 50 reading.
Australia publishes wage data for the third quarter on Wednesday. Trade statistics are due during the week from Singapore, Japan, India, New Zealand, Taiwan, Thailand and Malaysia. New Zealand reports food price data for October.
On the policy front, Bank Indonesia meets on Wednesday to decide whether to resume its easing cycle after holding in October. Last month’s inflation data came in hot, so authorities may stand pat again, with Governor Perry Warjiyo likely to signal room for further cuts in the coming year.
The Reserve Bank of Australia on Tuesday releases minutes from its November meeting, where it signaled an extended pause after leaving the cash rate at 3.6%. China will likely hold its 1- and 5-year loan prime rates steady on Thursday.
For more, read Bloomberg Economics’ full Week Ahead for Asia Europe, Middle East, Africa
Switzerland takes center stage after a momentous week for the country that featured both a belated US trade deal and a surge in the franc to a decade-high against the euro.
GDP data on Monday may reveal the economy shrank during the third quarter for the first time in more than two years, as exporters reeled from Trump’s earlier move to inflict tariffs of 39% on Swiss goods. Trade data come on Thursday, while central bank President Martin Schlegel speaks on monetary policy the following day.
In the UK, inflation on Wednesday is anticipated to show weakening to a five-month low of 3.5%, a result that might validate the Bank of England’s view that price pressures have peaked. Amid investor jitters and speculation on Chancellor Rachel Reeves’s Nov. 26 budget, the final public-finance data before that announcement comes on Friday.
Appearances by BOE officials Catherine Mann, Swati Dhingra and chief economist Huw Pill are also on the calendar.
Similarly, in the euro zone, several European Central Bank speakers are scheduled, including Vice President Luis de Guindos and chief economist Philip Lane on Monday, and President Christine Lagarde and Bundesbank chief Joachim Nagel on Friday.
Among the data highlights will be the flash readings of PMI numbers, and negotiated wages, both on Friday.
For more, read Bloomberg Economics’ full Week Ahead for EMEA Some monetary decisions are on the diary in the wider region:
Hungary is poised to keep its rate at an EU high of 6.5% on Tuesday, at a time when Prime Minister Viktor Orban is moving to loosen the budget before elections and with inflation stuck outside policymakers’ tolerance band. Also on Tuesday, Angola’s central bank may cut its benchmark — now at 19% — to bolster the economy as price growth continues to ease. The South African Reserve Bank is expected to resume its easing cycle on Thursday with a 25-basis-point reduction to 6.75%, after the National Treasury formally backed its new 3% inflation target. Egypt is also anticipated to lower its benchmark rate on Thursday, to 20% from 21%. Policymakers will still have to weigh a surprise jump in rents last month that caused inflation to accelerate for the first time since May. Latin America
Underwhelming GDP-proxy readings over the last four months in Brazil may have extended into the end of the third quarter as tight financial conditions and slower public spending weigh on demand.
Brazil’s 16 straight quarters of growth — the best run for Latin America’s No. 1 economy in more than two decades — appears about to end. Some analysts see the possibility of a technical recession in the second half of 2025.
On the monetary policy front, inflation-targeting central banks in two of the region’s smaller economies — Uruguay and Paraguay — meet in the coming week, while Mexico’s posts the minutes of its last meeting.
Banxico on Nov. 6 delivered its 11th straight rate cut, reducing borrowing costs to 7.25%, while shortening its guidance horizon to its next meeting.
A shift in language — removing “further adjustments” for “evaluate reducing the reference rate” — suggested to many analysts that the board is nearing a pause, though Governor Victoria Rodriguez Ceja does see a quarter-point cut to 7% next month as “highly likely.”
Third-quarter output reports are due from four of LatAm’s major economies. Mexico’s final data will all but certainly confirm negatives for both the quarter-on-quarter and year-on-year prints as headwinds abound.
Chile’s readings will likely dip, due largely to an accident that temporarily halted output at a major mine in the world’s top copper-producing nation.
By contrast, analysts see the economies of Peru and Colombia tuning out not insignificant bouts of political noise to actually accelerate in the third quarter.
For more, read Bloomberg Economics’ full Week Ahead for Latin America –With assistance from Brian Fowler, Laura Dhillon Kane, Vince Golle, Monique Vanek, Robert Jameson, Mark Evans, Piotr Skolimowski and Carla Canivete.
The current state of the small cell lung cancer (SCLC) treatment paradigm rests on meaningful efficacy gains with immunotherapy approaches, although there remains an urgent need to identify predictive biomarkers to better tailor therapy and explore the utility of agents beyond immune checkpoint inhibitors (ICIs), according to Christine Hann, MD, PhD.1
In a presentation at the 20th Annual New York Lung Cancers Symposium®, Hann highlighted how recently presented SCLC data inform treatment decision-making across the limited-stage and extensive-stage settings. She explored various findings with consolidation durvalumab (Imfinzi), ups and downs regarding atezolizumab (Tecentriq) data, and the importance of identifying novel biomarkers to further individualize SCLC management.
Hann is an associate professor of oncology at the Johns Hopkins School of Medicine and a physician at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland.
What are some of the most recent advances and setbacks in therapeutic development for LS-SCLC?
The ADRIATIC Trial
Hann began by discussing the significance of data that have been reported from the phase 3 ADRIATIC trial (NCT03703297), which is investigating durvalumab as consolidation therapy in patients with stage III inoperable limited-stage SCLC (LS-SCLC). Data presented at the 2024 ASCO Annual Meeting showed that patients who received durvalumab monotherapy (n = 264) experienced a median progression-free survival (PFS) of 16.6 months (95% CI, 10.2-28.2) vs 9.2 months (95% CI, 7.4-12.9) with placebo (n = 266; HR, 0.76; 95% CI, 0.61-0.95; P = .0161).2 The median overall survival (OS) was 55.9 months (95% CI, 37.3-not evaluable) vs 33.4 months (95% CI, 25.5-39.9) with placebo (HR, 0.73; 95% CI, 0.57-0.93; P = .0104).
Hann also homed in on the safety findings from ADRIATIC, which showed that patients in the durvalumab arm received a median of 9.0 doses (range, 1-26) of the treatment. In this arm, the rate of any-grade all-cause adverse effects (AEs) was 94.3%, and the rate of any-grade immune-mediated AEs was 32.1%. Notably, any-grade radiation pneumonitis was seen in 22.9% of patients in this arm.
“Notable findings [from subgroup analyses] were that [patients who received] once-daily and twice-daily [dosing] both seem to benefit [from durvalumab],” Hann said, adding that “These are trends, not absolutes.”
Based on these data, in December 2024, the FDA approved durvalumab for the treatment of adult patients with LS-SCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.3
Hann added that data from the durvalumab/tremelimumab of ADRIATIC are still awaited.
The NRG-LU005 Study
Hann pivoted to provide context about findings from the phase 3 NRG-LU005 trial (NCT03811002), which investigated the use of concurrent atezolizumab and chemoradiotherapy in patients with limited-stage disease. Data from the second planned interim analysis showed no PFS or OS improvements with the concurrent administration of atezolizumab and standard-of-care (SOC) chemoradiotherapy vs chemoradiotherapy alone.4
“This was reminiscent of data that we’ve seen in [the phase 3] PACIFIC-2 [trial (NCT03519971)],” Hann explained. “It seems like immunotherapy given concurrently with chemoradiation offers no benefit.”
Notably, data from the final analysis of PACIFIC-2 showed that concurrent administration of durvalumab and SOC chemoradiotherapy followed by consolidation durvalumab (n = 219) did not result in a significant PFS benefit vs placebo plus SOC chemoradiotherapy (n = 109; HR, 0.85; 95% CI, 0.65-1.12; P = .247).5
The ACHILES Trial
Additional data with atezolizumab in the context of chemoradiotherapy in LS-SCLC came from the phase 2 ACHILES trial (NCT03540420) and were presented at the 2025 ASCO Annual Meeting. In this study, patients who received consolidation atezolizumab after chemoradiotherapy (n = 85) had a median OS of 43.4 months (95% CI, 25.1-51.2); the median OS was 38.8 months (95% CI, 25.8-57.6) among patients who underwent observation following chemoradiotherapy (n = 85). Although there was a numerical improvement in OS in the atezolizumab arm, this did not meet statistical significance (HR, 1.14; 95% CI, 0.76-1.71; P = .53).6
“It’s notable that the observation arm performed better than [in] other studies,” Hann stated. “For immunotherapy in LS-SCLC, the [optimal population] are patients with at least stable disease after chemoradiation, [and the ideal treatment and duration are] up to 2 years of durvalumab consolidation, which improves PFS and OS. Toxicity is manageable. Benefits [were] observed over the different subgroups, so [we should be] comfortable [using] once-daily or twice-daily radiation and either platinum agent.”
Hann summarized that, so far, clinical trial data have not shown a benefit with atezolizumab given concurrently with chemoradiation as maintenance or consolidation therapy. However, she explained that data from ongoing phase 3 trials with immunotherapy agents in LS-SCLC may add nuance to the question of the optimal role for immunotherapy-based combinations, in terms of efficacy as well as safety.
What do clinical data indicate about the role of immunotherapy in patients with ES-SCLC?
Turning to paradigm-defining data in extensive-stage SCLC (ES-SCLC), Hann focused on the benefits and limitations seen with the use of first-line immunotherapy in the phase 3 Impower133 (NCT02763579) and CASPIAN (NCT03043872) trials.
“The trials were designed slightly differently, but the outcomes were similar,” she reported. “There is a small population [of patients who] are doing well [with frontline immunotherapy]. In the rest, we could probably use additional therapy. [Across clinical studies], whether [patients received] PD-1 or PD-L1 [inhibition plus platinum/etoposide], there seems to be consistent benefit [in terms of an] improvement in median OS.”
She then summarized the results of several combination studies in the ES-SCLC setting, concluding that most did not show efficacy benefits with immunotherapy combination regimens vs single-agent immunotherapy. However, she spotlighted the biomarker-based phase 2 SWOG S1929 trial (NCT04334941), which evaluated maintenance atezolizumab alone vs in combination with talazoparib in patients with SLFN11-positive ES-SCLC. In this trial, the median PFS was 4.2 months (80% CI, 2.8-4.7) in the talazoparib arm (n = 54) vs 2.8 months (80% CI, 2.0-2.9) in the atezolizumab monotherapy arm (n = 52; HR, 0.70; 80% CI, 0.52-0.94; 1-sided log-rank stratified P = .056).7
“[It is] important to show that a biomarker-based study could be conducted in SCLC,” she noted.
Furthermore, Hann highlighted data from the phase 3 IMforte trial (NCT05091567) of first-line maintenance therapy with lurbinectedin (Zepzelca) plus atezolizumab that were presented at ASCO 2025. In this trial, patients with ES-SCLC who received the combination (n = 242) achieved a median PFS by independent review facility of 5.4 months (95% CI, 4.2-5.8) vs 2.1 months (95% CI, 1.6-2.7) with atezolizumab monotherapy (n = 241; stratified HR, 0.54; 95% CI, 0.43-0.67; 2-sided P< .0001).8 The median OS was 13.2 months (95% CI, 11.9-16.4) with the combination vs 10.6 months (95% CI, 9.5-12.2) with atezolizumab alone (stratified HR, 0.73; 95% CI, 0.57-0.95; 2-sided P = .0174).
Notably, these data supported the October 2025 FDA approval of lurbinectedin plus atezolizumab or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as maintenance therapy for adult patients with ES-SCLC whose disease has not progressed after frontline induction therapy with atezolizumab or atezolizumab and hyaluronidase, carboplatin, and etoposide.9
“With these data, etoposide plus a PD-L1 inhibitor is standard frontline therapy,” Hann reported. “Lurbinectedin offers PFS and OS benefit when added to maintenance atezolizumab as an option for, I say, select [patients with SCLC]. They have to be pretty fit and technically [have] no brain metastases at presentation. Toxicities are predictable but can be significant.”
What may be the future role of biomarkers in SCLC?
Hann concluded her presentation by emphasizing the importance of finding predictive biomarkers to further refine the role of immunotherapy. Questions remain as to which patient populations would benefit most from immunotherapy as monotherapy vs part of combination regimens. Hann also noted the uncertainty around optimal treatment strategies for patients with small cell transformation from EGFR-mutant adenocarcinoma, acknowledging that although early data suggest that ICIs might not be the most effective in this population, other types of immunotherapies might provide better outcomes. She also emphasized the importance of developing therapies that are more effective than chemotherapy for patients who are not eligible to receive ICIs, including those with active autoimmune conditions, those who have undergone transplant, and those who have paraneoplastic syndrome.
References
Hann CL. Immunotherapy in SCLC: when, what, and how much? Presented at: 20th Annual New York Lung Cancers Symposium; November 15, 2025; New York, New York.
Spigel DR, Cheng Y, Cho BC, et al. ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). J Clin Oncol. 2024;42(suppl 17):LBA5. doi:10.1200/JCO.2024.42.17_suppl.LBA5
FDA approves durvalumab for limited-stage small cell lung cancer. FDA. December 4, 2024. Accessed November 15, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-limited-stage-small-cell-lung-cancer
NRG Oncology trial implies the addition of atezolizumab concurrently to standard of care does not improve survival in limited-stage small cell lung cancer. News release. NRG Oncology. September 30, 2024. Accessed November 15, 2025. https://www.nrgoncology.org/Home/News/Post/nrg-oncology-trial-implies-the-addition-of-atezolizumab-concurrently-to-standard-of-care-does-not-improve-survival-in-limited-stage-small-cell-lung-cancer
Bradley JD, Sugawara S, Lee KHH, et al. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2. ESMO Open. 2024;9(suppl 3):102986. doi:10.1016/j.esmoop.2024.102986
Gronberg BH, Aanerud M, Dumoulin DW, et al. Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC). J Clin Oncol. 2025;43(suppl 17):LBA8005. doi:10.1200/JCO.2025.43.17_suppl.LBA8005
Karim NFA, Miao J, Reckamp KL, et al. SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol. 2023;41(suppl 16):8504. doi:10.1200/JCO.2023.41.16_suppl.8504
Paz-Ares L, Borghaei H, Liu SV, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): primary results of the phase 3 IMforte trial. J Clin Oncol. 2025;43(suppl 16):8006. doi:10.1200/JCO.2025.43.16_suppl.8006
FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer. FDA. October 2, 2025. Accessed November 15, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-combination-atezolizumab-or-atezolizumab-and-hyaluronidase-tqjs-extensive?utm_medium=email&utm_source=govdelivery
Ag Growth International (TSX:AFN) just unveiled two new high-capacity grain conveyors, the FX4 SP and FX4 18S. This expands its lineup with equipment focused on mobility, efficiency, and durability for today’s farming operations.
See our latest analysis for Ag Growth International.
All eyes have been on Ag Growth International after the release of its upgraded conveyors, but the excitement has not stopped the share price from tumbling. Most recently, the company experienced a one-day share price return of -40.15% and a one-year total shareholder return of -61.79%. Even with ongoing product innovation, momentum has faded significantly, reminding investors that near-term risks remain key to the broader story.
If you’re looking beyond single stocks for your next idea, now is a prime moment to expand your search and discover fast growing stocks with high insider ownership
With shares down sharply despite these high-profile launches, the key question is whether Ag Growth International is now trading below its true value or if investors are right to be cautious about future growth prospects. Is this a buying opportunity, or is the market already pricing in all that lies ahead?
The most widely followed narrative indicates that Ag Growth International’s fair value is far above its last close. With the stock recently trading at CA$19.42 and the narrative’s fair value at CA$53.38, there is a dramatic disconnect between the current price and long-term projections. This sets the stage for a significant debate over what is driving analyst conviction for future upside.
Operational improvements, financial discipline, and innovation are enhancing margins, boosting cash flow, and positioning for long-term market leadership.
Read the complete narrative.
Curious why this price target is so aggressive? The narrative hinges on forecasts for a rapid margin turnaround powered by new growth engines. But what is the boldest assumption underpinning this outlook? Find out which key transformation is expected to propel both profit margins and earnings to levels that could drastically reshape the stock’s valuation story.
Result: Fair Value of $53.38 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, persistent weakness in the Farm segment or delays in reducing net debt could quickly undermine the positive outlook and weigh on future performance.
Find out about the key risks to this Ag Growth International narrative.
If you’re ready to challenge the consensus or want to dig into the numbers yourself, it only takes a few minutes to build your own perspective. Do it your way
A great starting point for your Ag Growth International research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
Don’t let smart opportunities pass you by. Give yourself an edge with innovative investment ideas that could take your portfolio to the next level.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AFN.TO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Earlier this month, Microchip Technology reported quarterly earnings showing a year-on-year drop in both revenue and net income, alongside a cautious forward guidance attributed to inventory correction pressures and a softer demand environment.
An important development for the company is the launch of the LAN866x series, which aims to ease network integration and reduce costs in automotive Ethernet applications by enabling software-less, efficient endpoint connectivity.
We’ll explore how Microchip’s subdued guidance and continued inventory challenges may influence its outlook for earnings and margin recovery.
AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.
To own shares of Microchip Technology today, you need confidence in its ability to recover from ongoing inventory corrections and margin pressure while capitalizing on secular trends like increased vehicle electrification and edge AI. While the new LAN866x series targets growth in automotive Ethernet, the bigger picture remains driven by managing excess inventory and restoring earnings momentum. The impact of this launch on short-term catalysts, such as margin recovery, is not material, as inventory normalization is still the central near-term challenge for the business.
Among recent announcements, the Ceva partnership to bring advanced Neural Processing Units into Microchip products stands out for its relevance to future growth catalysts. By embedding scalable AI directly in its compute, communication, and security solutions, Microchip aims to expand its reach in next-generation edge and data center markets, key drivers highlighted in the recovery narrative, beyond automotive network innovation.
However, investors should also consider that, unlike the upside from new product cycles, ongoing inventory write-offs and factory underutilization charges remain critical headwinds that…
Read the full narrative on Microchip Technology (it’s free!)
Microchip Technology’s outlook anticipates $6.6 billion in revenue and $1.4 billion in earnings by 2028. Achieving these targets implies an annual revenue growth rate of 15.9% and a $1.58 billion increase in earnings from the current level of -$178.4 million.
Uncover how Microchip Technology’s forecasts yield a $74.68 fair value, a 40% upside to its current price.
MCHP Community Fair Values as at Nov 2025
Six individual fair value estimates from the Simply Wall St Community range between US$22.39 and US$90 per share. Opinions vary, especially given persistent inventory challenges and their broader effects on profitability, so take the time to compare multiple views for a fuller picture.
Explore 6 other fair value estimates on Microchip Technology – why the stock might be worth less than half the current price!
Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.
Opportunities like this don’t last. These are today’s most promising picks. Check them out now:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MCHP.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Seagate Technology Holdings (STX) has caught investor attention as its stock makes notable moves this month. With the tech sector in flux, Seagate’s recent price performance offers a starting point for those eyeing value and growth potential.
See our latest analysis for Seagate Technology Holdings.
Seagate’s share price is up a jaw-dropping 198.89% year-to-date, with trend-defining gains over the past quarter and a 173.25% total shareholder return in the past year. This kind of momentum signals growing optimism from investors that the company’s turnaround is the real deal, especially as short-term swings work themselves out against the backdrop of dramatic long-term outperformance.
If you’re looking for the next big opportunity in tech, it makes sense to check out the latest movers and fast-risers. See the full list for free with our See the full list for free..
But given such rapid gains, is Seagate truly undervalued based on its fundamentals, or have expectations already pushed the price to reflect every bit of its future growth? Is there still a buying opportunity, or has the market already priced in what comes next?
Seagate’s most widely followed narrative suggests its fair value stands well above the last close price. This sets up a debate about whether strong profitability and innovation can power further upside.
Seagate is ramping up its HAMR-based Mozaic drives, which represent a technological breakthrough. The transition to these drives is expected to lead to sustained and profitable growth, impacting both revenue and net margins positively.
Read the complete narrative.
Want to know what’s fueling this bullish price target? The narrative builds its case on industry-defining innovation, with underlying projections that might challenge even the most optimistic expectations. See the full forecast breakdown and get the details that are moving the numbers.
Result: Fair Value of $277.25 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, unexpected shifts in trade policy or renewed industry competition could quickly challenge Seagate’s upbeat outlook and current valuation narrative.
Find out about the key risks to this Seagate Technology Holdings narrative.
If you have a different take or want to dive into the numbers yourself, it’s never been easier to put together your own story. Discover insights in just a few minutes and Do it your way.
A great starting point for your Seagate Technology Holdings research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
Don’t let opportunity pass you by when there are standout investment themes on Simply Wall Street’s Screener. Make your next smart move today and you might just spot your new favorite stock.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include STX.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Adidas is kicking off Black Friday with an early sale that includes must-see deals on a wide range of Adidas Sambas and more Adidas shoe styles.
The Adidas early Black Friday sale gives adiClub members first access to discounts of up to 60% off. You do need to join the adiClub to unlock these deals, but it’s free to join and you will get access to reduced prices on Sambas, Adidas Gazelles, Adidas Handball Spezials, and much more before everyone else.
There’s more than just footwear on sale. You can shop discounts on top styles, including matching sets, hoodies and sweatshirts, jackets and coats, fitness dresses, and more.
You’ll want to hurry if you want access to this early sale. It ends November 19. Snag your new pair of Adidas Sambas for $70 below!
